Tourmaline Stock Based Compensation vs Net Income Analysis

TRML Stock

19.77 1.02 5.44%

Tourmaline Bio financial indicator trend analysis is much more than just breaking down Tourmaline Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tourmaline Bio is a good investment. Please check the relationship between Tourmaline Bio Stock Based Compensation and its Net Income accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.

Stock Based Compensation vs Net Income

Stock Based Compensation vs Net Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tourmaline Bio Stock Based Compensation account and Net Income. At this time, the significance of the direction appears to have pay attention.

The correlation between Tourmaline Bio's Stock Based Compensation and Net Income is -0.9. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Net Income in the same time period over historical financial statements of Tourmaline Bio, assuming nothing else is changed. The correlation between historical values of Tourmaline Bio's Stock Based Compensation and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Tourmaline Bio are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Stock Based Compensation i.e., Tourmaline Bio's Stock Based Compensation and Net Income go up and down completely randomly.

Correlation Coefficient

-0.9

Relationship Direction	Negative
Relationship Strength	Significant

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Tourmaline Bio financial statement analysis. It represents the amount of money remaining after all of Tourmaline Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Most indicators from Tourmaline Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tourmaline Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.Selling General Administrative is expected to rise to about 23.9 M this year, although the value of Issuance Of Capital Stock will most likely fall to about 126 M.

	2022	2023	2024	2025 (projected)
Total Operating Expenses	19.7M	45.4M	89.7M	94.2M
Cost Of Revenue	6K	33K	29.7K	28.2K

Total Operating Expenses Cost Of Revenue

Tourmaline Bio fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Other Assets	Short Term Investments	Short Long Term Debt Total	Current Deferred Revenue	Net Invested Capital	Short Long Term Debt	Net Working Capital
Total Assets		0.74	0.98	1.0	-0.44	-0.28	-0.97	0.35	0.86	0.92	1.0	0.62	-0.2	0.93	0.95	0.16	1.0	-0.29	0.91	0.23	0.22	0.42	-0.15	0.95	-0.82	0.95
Other Current Liab	0.74		0.76	0.76	-0.64	-0.46	-0.73	0.49	0.53	0.6	0.75	0.2	-0.39	0.65	0.67	-0.1	0.75	-0.24	0.68	0.56	0.21	0.07	-0.34	0.68	-0.4	0.67
Total Current Liabilities	0.98	0.76		0.97	-0.53	-0.21	-0.99	0.29	0.91	0.96	0.96	0.68	-0.2	0.95	0.96	0.17	0.96	-0.17	0.97	0.3	0.24	0.39	-0.14	0.96	-0.88	0.94
Total Stockholder Equity	1.0	0.76	0.97		-0.42	-0.3	-0.97	0.36	0.85	0.91	1.0	0.58	-0.27	0.93	0.95	0.09	1.0	-0.26	0.91	0.22	0.26	0.37	-0.21	0.95	-0.81	0.94
Property Plant And Equipment Net	-0.44	-0.64	-0.53	-0.42		0.37	0.49	-0.45	-0.3	-0.39	-0.43	-0.25	-0.14	-0.34	-0.43	-0.35	-0.43	0.35	-0.48	-0.91	0.46	-0.41	-0.2	-0.42	0.34	-0.43
Net Debt	-0.28	-0.46	-0.21	-0.3	0.37		0.15	-0.99	0.12	-0.07	-0.33	0.26	0.3	-0.22	-0.28	0.21	-0.33	0.2	-0.03	-0.29	0.3	-0.27	0.26	-0.33	-0.1	-0.37
Retained Earnings	-0.97	-0.73	-0.99	-0.97	0.49	0.15		-0.22	-0.93	-0.97	-0.95	-0.74	0.12	-0.95	-0.97	-0.25	-0.96	0.18	-0.97	-0.25	-0.24	-0.43	0.06	-0.96	0.88	-0.95
Cash	0.35	0.49	0.29	0.36	-0.45	-0.99	-0.22		-0.05	0.14	0.4	-0.2	-0.29	0.29	0.35	-0.18	0.4	-0.23	0.11	0.35	-0.32	0.31	-0.25	0.39	0.0	0.43
Non Current Assets Total	0.86	0.53	0.91	0.85	-0.3	0.12	-0.93	-0.05		0.98	0.81	0.85	-0.12	0.94	0.91	0.21	0.82	0.1	0.97	0.03	0.43	0.32	-0.06	0.89	-0.95	0.86
Non Currrent Assets Other	0.92	0.6	0.96	0.91	-0.39	-0.07	-0.97	0.14	0.98		0.89	0.84	-0.08	0.97	0.97	0.27	0.89	0.0	0.97	0.1	0.3	0.46	-0.01	0.96	-0.93	0.95
Cash And Short Term Investments	1.0	0.75	0.96	1.0	-0.43	-0.33	-0.95	0.4	0.81	0.89		0.57	-0.21	0.9	0.93	0.14	1.0	-0.34	0.87	0.24	0.18	0.43	-0.16	0.94	-0.78	0.93
Common Stock Shares Outstanding	0.62	0.2	0.68	0.58	-0.25	0.26	-0.74	-0.2	0.85	0.84	0.57		0.38	0.73	0.76	0.63	0.58	0.08	0.76	-0.09	0.11	0.63	0.44	0.72	-0.81	0.72
Non Current Liabilities Total	-0.2	-0.39	-0.2	-0.27	-0.14	0.3	0.12	-0.29	-0.12	-0.08	-0.21	0.38		-0.26	-0.13	0.93	-0.21	-0.36	-0.19	0.05	-0.67	0.69	1.0	-0.17	0.1	-0.11
Other Current Assets	0.93	0.65	0.95	0.93	-0.34	-0.22	-0.95	0.29	0.94	0.97	0.9	0.73	-0.26		0.98	0.09	0.91	0.07	0.95	0.05	0.38	0.37	-0.19	0.98	-0.89	0.97
Other Stockholder Equity	0.95	0.67	0.96	0.95	-0.43	-0.28	-0.97	0.35	0.91	0.97	0.93	0.76	-0.13	0.98		0.22	0.94	-0.07	0.93	0.13	0.23	0.51	-0.06	1.0	-0.87	0.99
Total Liab	0.16	-0.1	0.17	0.09	-0.35	0.21	-0.25	-0.18	0.21	0.27	0.14	0.63	0.93	0.09	0.22		0.14	-0.43	0.17	0.18	-0.6	0.83	0.95	0.18	-0.22	0.23
Total Current Assets	1.0	0.75	0.96	1.0	-0.43	-0.33	-0.96	0.4	0.82	0.89	1.0	0.58	-0.21	0.91	0.94	0.14		-0.33	0.88	0.24	0.19	0.43	-0.16	0.94	-0.79	0.94
Common Stock	-0.29	-0.24	-0.17	-0.26	0.35	0.2	0.18	-0.23	0.1	0.0	-0.34	0.08	-0.36	0.07	-0.07	-0.43	-0.33		0.01	-0.49	0.58	-0.42	-0.34	-0.07	-0.06	-0.11
Accounts Payable	0.91	0.68	0.97	0.91	-0.48	-0.03	-0.97	0.11	0.97	0.97	0.87	0.76	-0.19	0.95	0.93	0.17	0.88	0.01		0.23	0.35	0.31	-0.12	0.92	-0.94	0.89
Other Assets	0.23	0.56	0.3	0.22	-0.91	-0.29	-0.25	0.35	0.03	0.1	0.24	-0.09	0.05	0.05	0.13	0.18	0.24	-0.49	0.23		-0.48	0.13	0.07	0.12	-0.09	0.12
Short Term Investments	0.22	0.21	0.24	0.26	0.46	0.3	-0.24	-0.32	0.43	0.3	0.18	0.11	-0.67	0.38	0.23	-0.6	0.19	0.58	0.35	-0.48		-0.61	-0.67	0.23	-0.28	0.16
Short Long Term Debt Total	0.42	0.07	0.39	0.37	-0.41	-0.27	-0.43	0.31	0.32	0.46	0.43	0.63	0.69	0.37	0.51	0.83	0.43	-0.42	0.31	0.13	-0.61		0.73	0.5	-0.37	0.56
Current Deferred Revenue	-0.15	-0.34	-0.14	-0.21	-0.2	0.26	0.06	-0.25	-0.06	-0.01	-0.16	0.44	1.0	-0.19	-0.06	0.95	-0.16	-0.34	-0.12	0.07	-0.67	0.73		-0.1	0.04	-0.04
Net Invested Capital	0.95	0.68	0.96	0.95	-0.42	-0.33	-0.96	0.39	0.89	0.96	0.94	0.72	-0.17	0.98	1.0	0.18	0.94	-0.07	0.92	0.12	0.23	0.5	-0.1		-0.85	1.0
Short Long Term Debt	-0.82	-0.4	-0.88	-0.81	0.34	-0.1	0.88	0.0	-0.95	-0.93	-0.78	-0.81	0.1	-0.89	-0.87	-0.22	-0.79	-0.06	-0.94	-0.09	-0.28	-0.37	0.04	-0.85		-0.82
Net Working Capital	0.95	0.67	0.94	0.94	-0.43	-0.37	-0.95	0.43	0.86	0.95	0.93	0.72	-0.11	0.97	0.99	0.23	0.94	-0.11	0.89	0.12	0.16	0.56	-0.04	1.0	-0.82

Click cells to compare fundamentals

Tourmaline Bio Account Relationship Matchups

Tourmaline Bio fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	152.8M	150K	9.1M	210.3M	309.0M	324.5M
Other Current Liab	2.6M	32K	800K	3.7M	5.3M	2.7M
Total Current Liabilities	3.4M	376K	1.4M	5.0M	8.9M	9.4M
Total Stockholder Equity	148.0M	(226K)	(19.7M)	205.0M	300.1M	315.1M
Property Plant And Equipment Net	2.0M	4.8M	570K	447K	267K	253.7K
Retained Earnings	(43.0M)	(226K)	(19.9M)	(62.1M)	(135.3M)	(128.5M)
Cash	17.6M	150K	8.3M	140.7M	30.5M	43.3M
Non Current Assets Total	2.0M	4.9M	786K	1.4M	40.2M	42.2M
Non Currrent Assets Other	14.0K	104K	216K	974K	3.3M	3.4M
Cash And Short Term Investments	149.5M	150K	8.3M	203.0M	258.3M	271.2M
Common Stock Shares Outstanding	668.5K	10.9M	20.3M	4.7M	25.3M	26.6M
Liabilities And Stockholders Equity	152.8M	150K	9.1M	210.3M	309.0M	324.5M
Non Current Liabilities Total	1.4M	626K	27.5M	251K	40K	38K
Other Current Assets	1.3M	2.5M	54K	5.9M	10.5M	11.1M
Other Stockholder Equity	4.9M	78K	167.9K	267.0M	435.0M	456.8M
Total Liab	4.8M	376K	28.8M	5.3M	8.9M	9.3M
Total Current Assets	150.8M	150K	8.3M	208.9M	268.8M	282.3M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Prophet

When determining whether Tourmaline Bio is a strong investment it is important to analyze Tourmaline Bio's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Tourmaline Bio's future performance. For an informed investment choice regarding Tourmaline Stock, refer to the following important reports:

How To Invest In Tourmaline

Details

Is Tourmaline Stock a good investment?

Details

What is Tourmaline Bio's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tourmaline Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy Tourmaline Stock please use our How to buy in Tourmaline Stock guide.

You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tourmaline Bio. If investors know Tourmaline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tourmaline Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.23)

Return On Assets

(0.19)

Return On Equity

(0.26)

The market value of Tourmaline Bio is measured differently than its book value, which is the value of Tourmaline that is recorded on the company's balance sheet. Investors also form their own opinion of Tourmaline Bio's value that differs from its market value or its book value, called intrinsic value, which is Tourmaline Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tourmaline Bio's market value can be influenced by many factors that don't directly affect Tourmaline Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Tourmaline Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tourmaline Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tourmaline Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

Tourmaline Stock Based Compensation vs Net Income Analysis

Stock Based Compensation vs Net Income

Stock Based Compensation vs Net Income Correlation Analysis

Correlation Coefficient

Stock Based Compensation

Net Income

Tourmaline Bio fundamental ratios Correlations

Tourmaline Bio Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Tourmaline Bio fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Cash And Short Term Investments

Cash	- 0.99	Net Debt
Retained Earnings	- 0.99	Total Current Liabilities
Accounts Payable	- 0.97	Retained Earnings
Other Stockholder Equity	- 0.97	Retained Earnings
Non Currrent Assets Other	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Total Stockholder Equity